Currently, several Phase III outcome trials with SGLT2 inhibitors in non-diabetic HF patients with preserved (HFpEF) and reduced ejection fraction (HFrEF) are planned and the field is eagerly awaiting the results. The gene discussed is SLC5A2; the disease is hydrops fetalis.